{arrow_up} Back to top

Risk Minimisation Materials

Search by company, common medicine name, or title of Risk Minimisation Material

0-9 ABCDEFGHIJKLMNOPQRSTUVWXYZ

Zeposia

Bristol Myers Squibb Pharmaceuticals limited

{pdf_link}

Zeposia (ozanimod) Healthcare Professional Prescriber’s Checklist

{healthcare_pro_orange} For Healthcare Professionals

This risk minimisation material is a condition of the marketing authorisation. The Prescriber's Checklist includes information on the ozanimod treatment initiation criteria (including re-initiation); monitoring parameters prior to, during and after treatment with ozanimod, counselling points for patients and pregnancy prevention for women of childbearing potential. Recent updates made to this material reflect changes made to the Summaries of Product Characteristics (SPCs) for ozanimod regarding dosing in patients with mild or moderate hepatic impairment (Child-Pugh class A or B).

{pdf_link}

Zeposia (ozanimod) Patient/Caregiver Guide

This risk minimisation material is a condition of the marketing authorisation. This guide should be provided to patients, or caregivers of patients, receiving treatment with ozanimod as it provides important information including what patients need to be aware of before they start taking ozanimod, the signs and symptoms of important side effects they need to look out for during treatment and how to report side effects.

{pdf_link}

Zeposia (ozanimod) Pregnancy-specific Patient Reminder Card

This risk minimisation material is a condition of the marketing authorisation. This card should be provided to women of childbearing potential receiving treatment with ozanimod. It contains information on the potential risks if ozanimod is used during pregnancy, how to minimise these risks through pregnancy prevention and what the patient should do if they become pregnant while on treatment with ozanimod.

Zessly

Sandoz Limited

{pdf_link}

Zessly Patient Alert Card

Zessly Patient Alert Card

Zeyzelf

Luye Pharma Limited

{pdf_link}

Rivastigmine patch (Zeyzelf) - Instructions for use and patient diary - for patients

Instructions for use and a patient diary including medication record sheets for patients that have been prescribed Zeyzelf Patch (rivastigmine transdermal system) to ensure the correct use of the patch.

Ziagen

ViiV Healthcare UK Ltd

{external_link}

Abacavir Hypersensitivity Website for Healthcare Professionals

{healthcare_pro_orange} For Healthcare Professionals

Abacavir Hypersensitivity Website for Healthcare Professionals

Zoledronic acid

Dr. Reddy's Laboratories (UK) Ltd

{pdf_link}

A Patient's Guide to Zoledronic acid Dr. Reddy's 5mg/100ml Solution for Infusion in Osteoporosis

Brochure for Patients with Increased Risk of Bone Fractures

{pdf_link}

Zoledronic acid 5mg/100ml solution for infusion patient reminder card

The reminder card contains important information that you need to be aware of before and during treatment with zoledronic acid (5mg solution for infusion).

Ranbaxy (UK) Limited a Sun Pharmaceutical Company

{pdf_link}

Doctor's information guide

{healthcare_pro_orange} For Healthcare Professionals

Doctor's information guide - Zoledronic acid 5 mg

{pdf_link}

Patient information guide

Patient information guide - Zoledronic acid 5 mg

{pdf_link}

Zoledronic Acid 5 mg solution for infusion - ONJ

Zoledronic Acid 5 mg solution for infusion - ONJ - patient reminder card

Seacross Pharmaceuticals Ltd

{pdf_link}

DOCTOR'S INFORMATION GUIDE

This information is part of the Risk Management Plan (RMP) for Zoledronic acid Seacross 5mg/100ml solution for infusion (hereafter refers as Zoledronic acid Seacross 5mg/100ml), and aims at minimisation of identified and potential therapy-related risks in order to optimize the benefit/risk balance. For complete information read the registered Summary of Product Characteristics of Zoledronic acid Seacross 5 mg/100ml before you prescribe Zoledronic acid Seacross 5mg/100ml.

{pdf_link}

ONJ-Patient Reminder Card

This reminder card containsimportant safety information that you need to be aware of before and during treatment with zoledronic acid(4mg/5ml,concentrate for solution for infusion; 4mg/100ml, solution for infusion)injections for cancer-related conditions

{pdf_link}

PATIENT INFORMATION GUIDE

This brochure is intended for patients with an increased risk of bone fractures that are going to be treated with Zoledronic acid Seacross 5mg/100ml solution for infusion(Hereafter refer as Zoledronic acid Seacross 5mg/100ml). Read this brochure carefully because it gives you important information about Zoledronic acid Seacross 5mg/100ml. Please also read the package leaflet ofZoledronic acid Seacross 5mg/100ml for more information.

{pdf_link}

PATIENT REMINDER CARD

This reminder card contains important safety information that you need to be aware of before and during treatment with Zoledronic acid Seacross 5mg/100ml solution for infusion.

Mylan

{pdf_link}

Patient Reminder Card for osteonecrosis of the jaw

Patient reminder card for osteonecrosis of the jaw before and during treatment with zoledronic acid (4mg/100ml solution for infusion; 4mg/5ml concentrate for solution for infusion) injections

Tillomed Laboratories Ltd

{pdf_link}

Zoledronic Acid 4mg/5ml Concentrate for Solution for Infusion

Patient Reminder Card - Osteonecrosis of the jaw

Morningside Healthcare Ltd

{pdf_link}

Zoledronic Acid Patient Card

{healthcare_pro_orange} For Healthcare Professionals

This reminder card contains important safety information that you need to be aware of before and during treatment with Zoledronic acid (4mg/5ml, concentrate for solution for infusion) injection for cancer-related conditions

Martindale Pharma, an Ethypharm Group Company

{pdf_link}

Zoledronic Acid Patient Card

Zoledronic Acid Patient Card This reminder card contains important safety information that you need to be aware of before and during treatment with Zoledronic acid (5mg solution for infusion).

{pdf_link}

Zoledronic acid patient card

Zoledronic Acid Patient Card This reminder card contains important safety information that you need to be aware of before and during treatment with Zoledronic acid (4mg/100ml solution for infusion; 4mg/5ml concentrate for solution for infusion) injections for cancer-related conditions.

Zolgensma

Novartis Pharmaceuticals UK Ltd

{pdf_link}

Zolgensma Caregiver Guide

{healthcare_pro_orange} For Healthcare Professionals

A caregiver’s guide to Zolgensma®

{pdf_link}

Zolgensma Healthcare Professional Guide

{healthcare_pro_orange} For Healthcare Professionals

A healthcare professional’s guide to minimising risks with Zolgensma

Zypadhera

Eli Lilly and Company Limited

{pdf_link}

ZYPADHERA 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection Patient Alert Card

ZYPADHERA 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection Patient Alert Card containing important safety information for patients.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.